The clinical study of thulium laser combined with intravesical instillation of pirarubicin in the treatment of non-muscle invasive bladder cancer

Abstract

Objective To investigate the clinical efficacy of transurethral thulium laser enucleation combined with intravesical instillation of pirarubicin in the treatment of non-muscle invasive bladder cancer. Methods The clinical data of 67 cases of non-muscle invasive bladder cancer who were treated in our hospital from January 2014 to January 2015 were analyzed retrospectively. Including 56 cases single tumor and 11 cases multiple tumors, the tumor diameter ranged from 0.5 to 2.7 cm [mean (2.1±0.4)cm]. All patients were treated by transurethral thulium laser enucleation combined with immediate postoperative instillation of pirarubicin and maintenance instillation of pirarubicin. Regular cystoscopy after operation and long-term follow-up was performed. Results All the operations were successfully enucleationed tumor with once time. The average time of tumor enucleation was (17.3 ± 6.8)min, the intraoperative blood loss was no more than 10 mL. There was no dilutional hyponatremia, bladder perforation, obturator nerve reflex were found in all patients. Postoperative complications included 7 cases of mild hematuria, 2 cases of urinary tract infection, 1 case of urethral stricture, and all patients were cured by symptomatic treatment. Followed up for 6 to 24 months with a mean of (13.6±3.4)months. Five cases were lost to follow up, 8 cases (12.9%) had recu-rrence, 1 case (1.6%) had progression, 13 patients had grade I adverse reactions during intravesical instillation of pirarubicin. Conclusions The transurethral thulium laser enucleation combined with intravesical instillation of pirarubicin for treatment of non-muscle invasive bladder cancer is safe and effective, it is worthy of clinical application. Key words: Urinary Bladder Neoplasms; Thulium; Epirubicin